These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2. Xie J; Ding C; He J; Zhang Y; Ni S; Zhang X; Chen Q; Wang J; Huang L; He H; Li W; Ma H; Jin T; Zhang S; Gao Y Front Immunol; 2021; 12():715464. PubMed ID: 34539645 [TBL] [Abstract][Full Text] [Related]
5. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies. Pulvirenti F; Fernandez Salinas A; Milito C; Terreri S; Piano Mortari E; Quintarelli C; Di Cecca S; Lagnese G; Punziano A; Guercio M; Bonanni L; Auria S; Villani F; Albano C; Locatelli F; Spadaro G; Carsetti R; Quinti I Cells; 2021 Oct; 10(11):. PubMed ID: 34831138 [TBL] [Abstract][Full Text] [Related]
6. IgV somatic mutation of human anti-SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity. de Mattos Barbosa MG; Liu H; Huynh D; Shelley G; Keller ET; Emmer BT; Sherman E; Ginsburg D; Kennedy AA; Tai AW; Wobus C; Mirabeli C; Lanigan TM; Samaniego M; Meng W; Rosenfeld AM; Prak ETL; Platt JL; Cascalho M JCI Insight; 2021 May; 6(9):. PubMed ID: 33769311 [TBL] [Abstract][Full Text] [Related]
7. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Wang K; Jia Z; Bao L; Wang L; Cao L; Chi H; Hu Y; Li Q; Zhou Y; Jiang Y; Zhu Q; Deng Y; Liu P; Wang N; Wang L; Liu M; Li Y; Zhu B; Fan K; Fu W; Yang P; Pei X; Cui Z; Qin L; Ge P; Wu J; Liu S; Chen Y; Huang W; Wang Q; Qin CF; Wang Y; Qin C; Wang X Nature; 2022 Mar; 603(7903):919-925. PubMed ID: 35090164 [TBL] [Abstract][Full Text] [Related]
8. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287 [TBL] [Abstract][Full Text] [Related]
9. mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. Sokal A; Barba-Spaeth G; Fernández I; Broketa M; Azzaoui I; de La Selle A; Vandenberghe A; Fourati S; Roeser A; Meola A; Bouvier-Alias M; Crickx E; Languille L; Michel M; Godeau B; Gallien S; Melica G; Nguyen Y; Zarrouk V; Canoui-Poitrine F; Pirenne F; Mégret J; Pawlotsky JM; Fillatreau S; Bruhns P; Rey FA; Weill JC; Reynaud CA; Chappert P; Mahévas M Immunity; 2021 Dec; 54(12):2893-2907.e5. PubMed ID: 34614412 [TBL] [Abstract][Full Text] [Related]
10. Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Reynolds CJ; Gibbons JM; Pade C; Lin KM; Sandoval DM; Pieper F; Butler DK; Liu S; Otter AD; Joy G; Menacho K; Fontana M; Smit A; Kele B; Cutino-Moguel T; Maini MK; Noursadeghi M; ; Brooks T; Semper A; Manisty C; Treibel TA; Moon JC; ; McKnight Á; Altmann DM; Boyton RJ Science; 2022 Jan; 375(6577):183-192. PubMed ID: 34855510 [TBL] [Abstract][Full Text] [Related]
11. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Wang Z; Muecksch F; Schaefer-Babajew D; Finkin S; Viant C; Gaebler C; Hoffmann HH; Barnes CO; Cipolla M; Ramos V; Oliveira TY; Cho A; Schmidt F; Da Silva J; Bednarski E; Aguado L; Yee J; Daga M; Turroja M; Millard KG; Jankovic M; Gazumyan A; Zhao Z; Rice CM; Bieniasz PD; Caskey M; Hatziioannou T; Nussenzweig MC Nature; 2021 Jul; 595(7867):426-431. PubMed ID: 34126625 [TBL] [Abstract][Full Text] [Related]
12. Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ T cell responses. Balachandran H; Phetsouphanh C; Agapiou D; Adhikari A; Rodrigo C; Hammoud M; Shrestha LB; Keoshkerian E; Gupta M; Turville S; Christ D; King C; Sasson SC; Bartlett A; Grubor-Bauk B; Rawlinson W; Aggarwal A; Stella AO; Klemm V; Mina MM; Post JJ; Hudson B; Gilroy N; Konecny P; Ahlenstiel G; Dwyer DE; Sorrell TC; Kelleher A; Tedla N; Lloyd AR; Martinello M; Bull RA; Cell Rep; 2022 Feb; 38(6):110345. PubMed ID: 35090598 [TBL] [Abstract][Full Text] [Related]
13. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192 [TBL] [Abstract][Full Text] [Related]
14. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Wratil PR; Stern M; Priller A; Willmann A; Almanzar G; Vogel E; Feuerherd M; Cheng CC; Yazici S; Christa C; Jeske S; Lupoli G; Vogt T; Albanese M; Mejías-Pérez E; Bauernfried S; Graf N; Mijocevic H; Vu M; Tinnefeld K; Wettengel J; Hoffmann D; Muenchhoff M; Daechert C; Mairhofer H; Krebs S; Fingerle V; Graf A; Steininger P; Blum H; Hornung V; Liebl B; Überla K; Prelog M; Knolle P; Keppler OT; Protzer U Nat Med; 2022 Mar; 28(3):496-503. PubMed ID: 35090165 [TBL] [Abstract][Full Text] [Related]
15. Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex. Tang J; Grubbs G; Lee Y; Huang C; Ravichandran S; Forgacs D; Golding H; Ross TM; Khurana S EBioMedicine; 2021 Dec; 74():103748. PubMed ID: 34902788 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Pozzetto B; Legros V; Djebali S; Barateau V; Guibert N; Villard M; Peyrot L; Allatif O; Fassier JB; Massardier-Pilonchéry A; Brengel-Pesce K; Yaugel-Novoa M; Denolly S; Boson B; Bourlet T; Bal A; Valette M; Andrieu T; Lina B; ; Cosset FL; Paul S; Defrance T; Marvel J; Walzer T; Trouillet-Assant S Nature; 2021 Dec; 600(7890):701-706. PubMed ID: 34673755 [TBL] [Abstract][Full Text] [Related]
17. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection. Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK Front Immunol; 2021; 12():793953. PubMed ID: 34899762 [TBL] [Abstract][Full Text] [Related]